FLINT, Mich., Aug. 10, 2015 /PRNewswire/ -- Diplomat Pharmacy, Inc. (NYSE: DPLO) announced today that it will offer IRESSA® (gefitinib), recently approved by the U.S. Food and Drug Administration as a first-line therapy for a specific type of metastatic non-small cell lung cancer (NSCLC).
IRESSA is a once-daily oral medication that targets and blocks the activity of epidermal growth factor receptor-tyrosine kinase (EGFR-TK), an enzyme that regulates the intracellular signaling pathways implicated in cancer cell proliferation and survival. It is intended for the treatment of patients whose tumors express the most common types of EGFR mutations in NSCLC (exon 19 deletions or exon 21 L858R substitution mutations).
Lung cancer is the leading cause of cancer-related death among men and women in the United States. According to the National Cancer Institute, an estimated 221,200 Americans will be diagnosed with lung cancer this year, and 158,040 will die from the disease. NSCLC is the most common type of lung cancer. Mutations in the EGFR gene are present in about 10 percent of NSCLC tumors.
EGFR is a protein found in abnormally high levels on the surface of many types of cancer cells, particularly NSCLC cells. A patient's EGFR mutation status (positive or negative) can be confirmed by diagnostic testing using a sample of tumor tissue.
"We are excited to be able to offer select patients diagnosed with metastatic NSCLC another first-line treatment opportunity through IRESSA," said Gary Kadlec, president of Diplomat. "IRESSA tablets can be taken with or without food, offering an important option to help meet patients' needs."
IRESSA is designed to specifically target the tumor. Please see full prescribing information for IRESSA at http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206995s000lbl.pdf.
To learn more about Diplomat, visit www.diplomat.is.
This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements give current expectations or forecasts of future events or our future financial or operating performance. The forward-looking statements contained in this press release are based on management's good-faith belief and reasonable judgment based on current information. These statements are qualified by important risks and uncertainties, many of which are beyond our control, that could cause our actual results to differ materially from those forecasted or indicated by such forward-looking statements. For a discussion of such risks and uncertainties, you should review Diplomat's filings with the Securities and Exchange Commission, including "Risk Factors" in Diplomat's Annual Report on Form 10-K for the year ended December 31, 2014 and in subsequent reports filed with or furnished to the Securities and Exchange Commission. Except as may be required by any applicable laws, Diplomat assumes no obligation to publicly update such forward-looking statements, which are made as of the date hereof or the earlier date specified herein, whether as a result of new information, future developments or otherwise.
Diplomat (NYSE: DPLO) serves patients and physicians in all 50 states. Headquartered in Flint, Michigan, the company focuses on medication management programs for people with complex chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, HIV, specialized infusion therapy and many other serious or long-term conditions. Diplomat opened its doors in 1975 as a neighborhood pharmacy with one essential tenet: "Take good care of patients, and the rest falls into place." Today, that tradition continues—always focused on improving patient care and clinical adherence. For more information visit www.diplomat.is. Follow us on Twitter and LinkedIn and like us on Facebook.
CONTACT: Kali Lucas, Public Relations Coordinator 810.768.9580 | email@example.com
Gary Rice, RPh, MS, MBA, CSP, Vice President, Clinical Services 810.768.9863 | firstname.lastname@example.org
SOURCE Diplomat Pharmacy, Inc.